



## IMPACT OF HUMAN GENETICS ON DRUG R&D


Robert Plenge

American Society of Human Genetics

October 16, 2018


# The Problem

## Two fundamental challenges to drug R&D




#### **Deloitte Centre for Health Solutions**

#### Attrition: where things go wrong and what that costs



Paul et al. Nat Rev Drug Discovery (2010)

#### Attrition: where things go wrong and what that costs





Paul et al. Nat Rev Drug Discovery (2010)

#### Most late-stage failures are due to lack of efficacy

# Phase II failures (2008-2010)


#### Phase III failures (2007-2010)





#### Arrowsmith Nature Reviews Drug Discovery (2011)

#### Attrition: where things go wrong and what that costs




Paul et al. Nat Rev Drug Discovery (2010)

**A** Solution

We relied on preclinical models to pick targets and estimate efficacy in heterogeneous human populations


#### It was...







# Humans are the "model organism" of choice for new targets and precision medicine

#### But today...





Amodel







Nelson et al Nature Genetics 2015









## It is not common or rare...


## It is common and rare variants

An example in immunology

## Example of allelic series model: *TYK2*

- TYK2 is an intracellular signaling molecule (next slide)
- Rare, complete human knockout is associated with immunodeficiency and risk of infection
- Common protein coding alleles reduce TYK2 function and protect from risk of autoimmune disease (*e.g.*, psoriasis, RA, SLE, IBD)
- Same common alleles do not increase risk of infection

## IL23 signaling and psoriasis





LETTERS https://doi.org/10.1038/s41588-018-0216-7

## TYK2 gene

#### Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes


Harm-Jan Westra <sup>1,2,3,4,5,20</sup> , Marta Martínez-Bon Yang Luo <sup>1,2,3,4</sup> , Nikola Teslovich <sup>1,2,3,4</sup> , Jane Worth Lars Klareskog <sup>13</sup> , Solbritt Rantapaa-Dahlqvist <sup>14</sup> John A. Todd <sup>17</sup> , Steve Eyre <sup>9,10</sup> , Peter A. Nigrovic <sup>4,</sup> Soumya Raychaudhuri <sup>(1)</sup> , <sup>2,3,4,9,19*</sup>		5364 0188 7203	Dataset	Frequency		Odds Ratio	
				Cases	Controls	0.5	1 1 
		GIGIA	Combined	0.897	0.88		(reference) 🌑
			T1D	0.898	0.874		(reference) 🎃
			RA	0.896	0.877		(reference) 🌰
	<b>P1104A</b>	CIGIA	Combined	0.022	0.032		
			T1D	0.022	0.033		
			RA	0.023	0.034		
	<b>I684S</b>	GIGIC	Combined	0.081	0.088		— <b>—</b> i
			T1D	0.08	0.093		
			RA	0.081	0.089		— <b>—</b> !
( lov	w freq: A928V)						

#### SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE

#### AUTOIMMUNITY

# Resolving *TYK2* locus genotype-to-phenotype differences in autoimmunity

Calliope A. Dendrou,<sup>1</sup> Adrian Cortes,<sup>1,2</sup> Lydia Shipman,<sup>1</sup> Hayley G. Evans,<sup>1</sup> Kathrine E. Attfield,<sup>3</sup> Luke Jostins,<sup>2</sup> Thomas Barber,<sup>1</sup> Gurman Kaur,<sup>3</sup> Subita Balaram Kuttikkatte,<sup>3</sup> Oliver A. Leach,<sup>1</sup> Christiane Desel,<sup>1</sup> Soren L. Faergeman,<sup>1,4</sup> Jane Cheeseman,<sup>5</sup> Matt J. Neville,<sup>5,6</sup> Stephen Sawcer,<sup>7</sup> Alastair Compston,<sup>7</sup> Adam R. Johnson,<sup>8</sup> Christine Everett,<sup>8</sup> John I. Bell,<sup>9</sup> Fredrik Karpe,<sup>5,6</sup> Mark Ultsch,<sup>8</sup> Charles Eigenbrot,<sup>8</sup> Gil McVean,<sup>2</sup> Lars Fugger<sup>1,3,4</sup>\*




P1104A allele that protects from autoimmunity is associated with ~80% lossof-function (LoF) in C/C homozygous state

#### Same LoF allele has no obvious increased risk of infection

	Rs34536443 genotype				~80% LoF is						
	G/G	G/C	C/C	Total	not associated						
normal	In U.K. Biobank	105,794 (90.63%)	10,689 (9.16%)	249 (0.21%)	116,732 (100%)	with increased					
S	Mycobacterial	20 (86.96%)	3 (13.04%)	0 (0.00%)	23	infection					
	Specific bacterial (For example, <i>S. aureus</i> )	54 (90.00%)	5 (8.33%)	1 (1.67%)	60						
Infections	Specific viral (e.g. HSV, VZV, viral encephalitis)	93 (96.88%)	3 (3.12%)	0 (0.00%)	96						
	Mucocutaneous candidiasis	46 (88.46%)	6 (11.54%)	0 (0.00%)	52						
	Total	213 (92.21%)	17 (7.36%)	1 (0.43%)	231	Dendrou, et al. (2016) Science Translational Medicine					


#### P1104A protects from multiple autoimmune diseases






Science Translational Medicine

#### But *I684S* variant shows a more complicated pattern!




Dendrou, et al. (2016) Science Translational Medicine




infections

Risk of severe/recurring




Risk of autoimmune disease




Risk of autoimmune disease

# But matching *modality with mechanism* is challenging, especially selectivity over JAKs




HTS assay was used in a phenotypic screen to find selective inhibitors of TYK2 over other JAKs

Risk of autoimmune disease



#### 50-80% TYK2 inhibition safe and effective in Phase 2 (psoriasis)




Papp et al (2018) NEJM


# Emerging resources

# Mendelian randomization


## Mendelian randomization: nature's clinical trial




## Mendelian randomization: nature's clinical trial



# Genetics can bridge biomarker with clinical data, establishing a causal link for drug discovery




#### Large-scale proteomic databases are limiting



#### Emerging resource of pQTLs for MR

- Tested 3,622 plasma proteins in 3,301 healthy individuals from INTERVAL population cohort
- Identified 1,927 genetic associations with 1,478 proteins
- Example: *IL-6R* RA protective allele increases sIL-6R levels (see figure) but decreases membrane-bound IL6R
- Therapeutic hypothesis: preventing IL-6 signaling through IL-6R via blocking antibodies should treat RA symptoms

Sun, Maranville et al (2018) Nature




Mendelian randomization establishes a causal link between IL-6 pathway and risk of rheumatoid arthritis

$$G \rightarrow I \rightarrow D$$




# Thus, therapeutic targeting of IL-6R should be beneficial in treating RA patients

#### Tocilizumab mimics mutation by reducing IL-6R signaling



Phenome-wide association study (PheWAS)

#### Phenome-wide association studies (PheWAS)





IFIH1 gene

#### Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes

Harm-Jan Westra<sup>1,2,3,4,5,20</sup>, Marta Martínez-Bonet<sup>1,2,0</sup>, Suna C Yang Luo<sup>1,2,3,4</sup>, Nikola Teslovich<sup>1,2,3,4</sup>, Jane Worthington<sup>9,10</sup>, Javi Lars Klareskog<sup>13</sup>, Solbritt Rantapaa-Dahlqvist<sup>14</sup>, Wei-Min Che John A. Todd<sup>17</sup>, Steve Eyre<sup>9,10</sup>, Peter A. Nigrovic<sup>4,18</sup>, Peter K. Greg Soumya Raychaudhuri <sup>1</sup>,<sup>2,3,4,9,19\*</sup>

rs35667974 – protects from T1D rs72871627 – protects from T1D ATA haplotype – protects from T1D

C /io e	185 974 627					
e	14	Dataset	Frequency		Odds-ratio	
	rs211 rs356 rs728		Cases	Controls	0.4 1	
	GITIA	Combined T1D	0.621	0.599	(reference) (reference)	
	AICIA	Combined T1D	0.016 0.01	0.02 0.021		
	GITIG	Combined T1D	0.009 0.008	0.011 0.014		
	AITIA	Combined T1D	0.354 0.344	0.371 0.37		


TFRS

https://doi.org/10.1038/s41588-018-0216-7

### PheWAS example: IFIH1, autoimmunity, asthma


Vitiligo

- PheWAS in ~800,000 individuals from four population cohorts
- Tested 25 SNPs for association with 1,683 clinical endpoints
- 10 novel associations discovered
- Example: *IFIH1* LOF allele protects from autoimmunity (known) but increases risk of asthma (novel finding)
- <u>Therapeutic hypothesis</u>: inhibiting IFIH1 may be effective in some autoimmune diseases but may make asthma worse




Diogo et al (2018) Nature Communications (in press)

#### Predicted impact of therapeutic inhibition of IFIH1



#### FinnGen is a unique PheWAS resource



# In conclusion

## Summary

- The pharmaceutical industry needs human genetics
- Human genetics increases probability of success >2-fold
- An "allelic series" model can be used to
  - -prioritize new targets
  - -match modality to mechanism
  - -select pharmacodynamics biomarkers
  - -determine clinical indications
- *TYK2* represents a compelling example in human immunology
- MR and PheWAS represent emerging resources
- (See back-up slides for more details!)

# Questions?

